NINAMED PTY. LTD.

NINAMED PTY. LTD. , based in Australia, specializes in developing wearable neuromodulation technologies aimed at treating pelvic health disorders, providing innovative solutions for improved patient outcomes. NINAMED PTY.

LTD. is focused on creating neuromodulation devices that treat pelvic health issues. The company is headquartered in Victoria, Australia. In May 2026, NINAMED PTY.

LTD. raised USD 13. 75 million in series A funding led by Sprim Ventures, with participation from SV Health Investors. NinaMED focuses on the development of innovative neuromodulation technologies aimed at treating pelvic health disorders, specifically through the modulation of the Saphenous nerve.

Their flagship product, NiNA, is designed to treat conditions like overactive bladder, providing a noninvasive, drug-free solution. The technology targets the Saphenous nerve, introducing new treatment methodologies to enhance pelvic health function and quality of life. NinaMED caters to a broad clientele, including healthcare providers and institutions specializing in urology and pelvic health, primarily in the United States and Canada. NinaMED generates revenue through partnerships with healthcare providers and institutions, primarily via direct sales of their neuromodulation devices.

Their agreements with hospitals and clinics facilitate the integration of their products into treatment protocols for pelvic health disorders, particularly for conditions like overactive bladder. Specific pricing plans are not disclosed, but the company is focused on establishing long-term relationships with clients seeking effective treatment solutions. The company will use the May 2026 funding to support development of the NinaMED System, work toward regulatory approval, and expand its operations.